BiotechTube
Phoreus Biotech

Phoreus Biotech

San Diego, United States· Est.
phoreusbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Phoreus Biotech is an innovative drug delivery company leveraging a proprietary peptide nanoparticle (PNP) platform to address key challenges in modern therapeutics. Its technology is designed for broad cargo capability, targeted delivery, enhanced safety, and flexible administration routes like buccal, transdermal, and pulmonary. The company is currently in the preclinical development stage, having raised a $2 million seed round, and is led by a seasoned team with deep experience in biotech and drug development.

Drug DeliveryNanotechnology

Technology Platform

Peptide Nanoparticles (PNPs) - self-assembling peptide-based nanocarriers designed for broad therapeutic cargo encapsulation, targeted delivery, enhanced safety, and flexible administration routes (e.g., buccal, transdermal, pulmonary).

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The platform addresses major limitations in delivering next-generation therapeutics like mRNA, proteins, and gene therapies, targeting a multi-billion dollar market.
Its potential for non-invasive administration (e.g., patches, inhalers) could significantly improve patient compliance and open new treatment paradigms.
Success in eliminating cold-chain requirements for mRNA vaccines presents a major commercial opportunity in global health logistics.

Risk Factors

The technology is at a high-risk, preclinical stage with unproven efficacy and safety in humans.
The company has limited capital from a small seed round and faces significant financing risk to advance development.
It operates in a highly competitive landscape against established drug delivery technologies and well-funded competitors.

Competitive Landscape

Phoreus competes in the advanced drug delivery space against dominant lipid nanoparticle (LNP) providers (e.g., used in mRNA vaccines), as well as companies developing polymeric nanoparticles, viral vectors, and other peptide-based systems. Differentiation is claimed through improved safety, targeting, and route-of-administration flexibility compared to first-generation LNPs.

More companies in Drug Delivery & Formulation →More companies in United States →